Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

Inclusion Criteria:

• Patients of both genders older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
• Only patients who have not been treated with Atrovent® within the last year are to be considered for inclusion

Exclusion Criteria:

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® metered dose inhaler